Gaithersburg-based Emergent BioSolutions will manufacture one of the first potential vaccines to fight the Zika virus, it announced Monday.
Under a federal contract, Emergent (NYSE: EBS) will develop and manufacture the vaccine for the Biomedical Advanced Research and Development Authority (BARDA), which is part of the U.S. Department of Health and Human Services. Emergent will develop the vaccine material from a base created by an undisclosed private company, university or institution and provided by BARDA, officials said.